UC Davis establishes Center for Experimental Therapeutics in Cancer for commercialization of therapies

Longevity Consortium receives $45M grant

The Longevity Consortium received a five-year, $45 million grant to move the consortium’s work to its next stage: integrating results from numerous studies about the factors that contribute to longer and healthier lives.

November 01, 2024

Vol.50 No.41

In Brief

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Miguel Villalona Calero was named deputy director of the University of California, Irvine Chao Family Comprehensive Cancer Center and division chief for hematology/oncology. He will start on July 8.

June 28, 2024

Vol.50 No.26

Clinical Roundup

Innovative PET scanner could change the way lung cancer is evaluated and treatment is assessed

Scientists at UC Davis Comprehensive Cancer and the UC Davis Department of Radiology have discovered a novel way to image the unique blood supply of the lungs. Their findings, published in the Journal of Nuclear Medicine, suggest the new method could help determine if lung cancer treatment is working.

June 14, 2024

Vol.50 No.24

In Brief

David Tom Cooke named associate director of Office of Inclusion, Diversity, Equity and Accessibility at UC Davis

David Tom Cooke was named associate director of the Office of Inclusion, Diversity, Equity and Accessibility (IDEAL) at University of California Davis Comprehensive Cancer Center.

May 17, 2024

Vol.50 No.20

Clinical Roundup

UC Davis study: TB vaccine shrinks liver cancer tumors in mice

A UC Davis Health study found that a single dose of Bacillus Calmette-Guérin, or BCG, the vaccine for tuberculosis, reduced liver tumor burden and extended the survival of mice with liver cancer. The study, published in Advanced Science, is the first to show the promising effects of the vaccine in treating liver cancer.

March 08, 2024

Vol.50 No.10

Clinical Roundup

UC Davis researchers identify “switch” to activate cancer cell death

A research team from the UC Davis Comprehensive Cancer Center has identified a crucial epitope (a protein section that can activate the larger protein) on the CD95 receptor that can cause cells to die.

October 27, 2023

Vol.49 No.40

UC Davis establishes Center for Experimental Therapeutics in Cancer for commercialization of therapies

YOU MAY BE INTERESTED IN

Longevity Consortium receives $45M grant

Miguel Villalona Calero named deputy director of UC Irvine Chao Family CCC

Innovative PET scanner could change the way lung cancer is evaluated and treatment is assessed

David Tom Cooke named associate director of Office of Inclusion, Diversity, Equity and Accessibility at UC Davis

UC Davis study: TB vaccine shrinks liver cancer tumors in mice

UC Davis researchers identify “switch” to activate cancer cell death

Renew today!

Subscriber content

Never miss an issue!

Login